16 January 2007, Godalming, UK. Sinclair Pharma plc (SPH.L), the specialty pharmaceutical company, announces that its UK subsidiary Ashbourne Pharmaceuticals has signed a marketing agreement with the German company Hennig Arzneimittel GmbH for the vertigo product Arlevert, and will today launch the product. The Arlevert deal launches Ashbourne's 'product fostering' concept, offering companies an initial low-risk product sales and evaluation period in the UK dispensing doctor market. After this initial fostering period, there is the opportunity to expand product sales to the secondary care market in the UK and Europe through Sinclair's other sales channels. Product fostering also provides a number of other services; as part of the Arlevert agreement, Ashbourne has been instrumental in gaining reimbursement, performing market research and developing the product sales and marketing strategy. The UK launch for Arlevert is initially intended to generate sales within Ashbourne's traditional customer group, UK dispensing doctors. However in the long term it is intended to foster the broader UK market. Sinclair is building a UK specialist salesforce to complement its European sales presence; these UK specialist salespeople will be able to co-promote products alongside Ashbourne. Ashbourne has a successful track record of co-promoting products into the niche dispensing doctor sector in the UK. The product fostering concept has been developed since Ashbourne was acquired by Sinclair in September 2006. Leslie Galloway, CEO of Ashbourne Pharmaceuticals, said: "Fostering offers partner companies a low risk and complete facility to launch and evaluate products in the UK market. We have already seen significant interest in the idea; many companies are interested in Ashbourne as a precursor to broader UK sales, and also potentially for European sales. We see many synergies with Sinclair's growing European specialist salesforce." Danilo Casadei Massari, VP Corporate Development of Sinclair, said: "Product fostering meets the needs of many companies wanting to research and test their product in the UK. Ashbourne offers a market-entry service, and synergies with the Sinclair Group mean that there are roll-out opportunities for sales and marketing activities in other EU markets. In 2007, Sinclair aims to complete the establishment and consolidation of its specialist salesforces in the five key EU territories and in the Nordic region, strengthening our position as an attractive commercial partner for Europe. Arlevert is one of the first products in a specialist portfolio that will be completed within 2007 and enable Sinclair to start its commercial organization in the UK" - ends - Enquiries: Capital MS&L Tel: +44 (0) 207 307 5330 Mary Clark, Halina Kukula Sinclair Pharma plc Tel: +44 (0) 1483 410600 Michael Flynn, CEO Zoe McDougall Tel: +44 (0) 7973 792 520 John Barrington-Carver Tel: +44 (0) 7831 655 630 Notes to editors: Arlevert and Vertigo Vertigo is a false sense of motion or spinning that can cause dizziness or nausea. It can occur as a result of a problem with the central nervous system ("central vertigo") or if there is a problem with the inner ear ("peripheral vertigo"). Arlevert is indicated to treat both central and peripheral vestibular vertigo and will be the only combination product available in the UK to effectively do so. Hennig Arzneimittel GmbH Based in Flörsheim, Hennig Arzneimittel is one of the oldest research-based private pharmaceutical companies in Germany. Hennig combines a domestic sales force and the most advanced manufacturing facilities to address the German healthcare market. Their research and development facilities focus on an evidence based approach to the development of pharmaceutical products. Ashbourne Pharmaceuticals Ltd Ashbourne Pharmaceuticals is a UK sales and marketing organisation, with a successful track record of co-promoting pharmaceutical products to UK dispensing doctors for more than 20 years. Ashbourne was acquired by Sinclair Pharma plc in September 2006. Dispensing doctors provide dispensary services for patients who live more than one mile from a retail pharmacy. They need to generate an income from these dispensing services in order to cover associated costs. Ashbourne co-promotes specific products to these doctors, also providing them with unique products and services that support their dispensing practice. Dispensing doctors account for an estimated 18% of the UK primary care market by value. Ashbourne is currently seeking rights to products that may be sold by both the existing Ashbourne existing sales force, and in the future the UK Sinclair salesforce (targeting other healthcare professionals such as specialists). Sinclair Pharma plc Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 60 countries. Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short time frame. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward- looking statements due to a variety of factors.